A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
Conditions: Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung Interventions: Drug: SI-B001; Drug: Docetaxel Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Docetaxel | Non-Small Cell Lung Cancer | Research | Skin Cancer | Squamous Cell Carcinoma | Study | Taxotere